Skip to main content

Table 3 Relationship between inflammatory related sequence variants and prostate cancer risk among U.S. and Jamaican men

From: The impact of genetic variants in inflammatory-related genes on prostate cancer risk among men of African Descent: a case control study

Genes

dbSNP ID location predicted function

Genotype

Unadjusted OR (95%CI) US men†

Age-adjusted OR (95%CI) US men†

Unadjusted OR (95%CI) Jamaican men†

Age-adjusted OR (95%CI) Jamaican men†

p-value US menǂ

p-value Jamaican menǂ

p-trend US men

p-trend Jamaican men

IL1B

rs1071676

GG

1.00 (referent)

1.00 (referent)

1.00 (referent)

1.00 (referent)

0.050

0.550

0.022

0.276

 

UTR'3

GC

0.72 (0.48, 1.10)

0.70 (0.42, 1.14)

1.39 (0.71, 2.70)

1.28 (0.62, 2.64)

0.124

0.338

  
 

miRNA

CC

0.16 (0.02, 1.25)

0.19 (0.02, 2.00)

2.02 (0.18, 22.8)

1.15 (0.10, 14.6)

0.035

0.500

  
  

GC + CC

0.66 (0.44, 1.00)

0.66 (0.40, 1.10)

1.42 (0.74, 2.72)

1.26 (0.62, 2.60)

0.050

0.294

  
  

CC vs (GG + GC)

0.18 (0.02, 1.36)

0.21 (0.02, 2.18)

1.89 (0.16, 21.1)

1.10 (0.08, 13.7)

0.046

0.525

  

IL1B

rs1143634

GG

1.00 (referent)

1.00 (referent)

1.00 (referent)

1.00 (referent)

0.051

0.447

0.016

0.203

 

Exon 4

GA

0.67 (0.44, 1.01)

0.65 (0.40, 1.06)

1.51 (0.76, 3.00)

1.37 (0.64, 2.90)

0.058

0.243

  
 

Splicing

AA

0.21 (0.02, 1.60)

0.24 (0.02, 2.86)

2.05 (0.18, 23.0)

1.16 (0.10, 14.6)

0.080

0.496

  
  

GA + AA

0.63 (0.42, 0.95)

0.62 (0.38, 1.02)

1.54 (0.78, 3.00)

1.36 (0.65, 2.82)

0.028

0.208

  
 

cds-synonymous

AA vs (GG + GA)

0.23 (0.02, 1.80)

0.27 (0.02, 3.20)

1.89 (0.16, 21.1)

1.10 (0.08, 13.7)

0.105

0.525

  

IL1R2

rs11886877

GG

1.00 (referent)

1.00 (referent)

1.00 (referent)

1.00 (referent)

0.007

0.889

0.002

0.631

 

Intron 1

GA

1.60 (1.08, 2.40)

1.63 (1.00, 2.64)

0.92 (0.50, 1.68)

0.94 (0.48, 1.80)

0.020

0.782

  
  

AA

2.34 (1.31, 4.16)

2.75 (1.38, 5.50)

0.82 (0.36, 1.86)

0.94 (0.38, 2.30)

0.004

0.633

  
  

GA + AA

1.72 (1.18, 2.52)

1.82 (1.14, 2.88)

0.89 (0.50, 1.58)

0.94 (0.50, 1.74)

0.005

0.700

  
  

AA vs (GG + GA)

1.76 (1.04, 2.96)

2.05 (1.10, 3.80)

0.86 (0.40, 1.80)

0.97 (0.43, 2.20)

0.033

0.691

  

RNASEL

rs12135247

AA

1.00 (referent)

1.00 (referent)

1.00 (referent)

1.00 (referent)

0.800

0.025

0.909

0.216

 

UTR'3

AG

1.06 (0.72, 1.58)

1.14 (0.71, 1.84)

2.17 (1.14, 4.12)

2.10 (1.04, 4.24)

0.756

0.018

  
 

TFBS

GG

0.77 (0.30, 1.96)

0.70 (0.24, 2.10)

0.45 (0.08, 2.40)

0.28 (0.04, 1.70)

0.570

0.284

  
 

miRNA

AG + GG

1.02 (0.70, 1.50)

1.07 (0.68, 1.68)

1.81 (0.99, 3.30)

1.68 (0.88, 3.24)

0.906

0.053

  
  

GG vs (AG + AA)

0.76 (0.30, 1.92)

0.67 (0.22, 1.97)

0.36 (0.06, 1.91)

0.22 (0.04, 1.35)

0.555

0.196

  

TNF

rs1800629

GG

1.00 (referent)

1.00 (referent)

1.00 (referent)

1.00 (referent)

0.101

0.782

0.113

0.549

 

5′ near gene

GA

1.50 (1.03, 2.20)

1.52 (0.96, 2.42)

1.21 (0.68, 2.12)

1.41 (0.78, 2.63)

0.034

0.518

  
 

TFBS

AA

0.90 (0.28, 2.80)

1.51 (0.36, 6.24)

1.00 (0.06, 16.3)

1.00 (0.06, 17.2)

0.551

0.752

  
  

GA + AA

1.44 (0.99, 2.10)

1.53 (0.97, 2.40)

1.20 (0.68, 2.10)

1.40 (0.75, 2.60)

0.050

0.525

  
  

AA vs (GG + GA)

0.78 (0.25, 2.42)

1.32 (0.32, 5.40)

0.94 (0.06, 15.2)

0.88 (0.05, 15.0)

0.452

0.734

  

IL1A

rs1800587

GG

1.00 (referent)

1.00 (referent)

1.00 (referent)

1.00 (referent)

0.088

0.450

0.028

0.224

 

UTR'5

GA

0.75 (0.50, 1.10)

0.68 (0.42, 1.08)

1.38 (0.76, 2.50)

1.42 (0.74, 2.72)

0.144

0.297

  
 

TFBS

AA

0.56 (0.32, 0.96)

0.78 (0.40, 1.53)

1.56 (0.69, 3.50)

1.64 (0.70, 4.00)

0.038

0.279

  
 

Splicing (ESE or

GA + AA

0.70 (0.48, 1.00)

0.70 (0.45, 1.10)

1.42 (0.80, 2.50)

1.47 (0.80, 2.72)

0.053

0.222

  
 

ESS)

AA vs (GG + GA)

0.66 (0.40, 1.10)

0.96 (0.52, 1.80)

1.30 (0.62, 2.70)

1.34 (0.60, 3.00)

0.105

0.478

  

IL10RA

rs4252243

GG

1.00 (referent)

1.00 (referent)

1.00 (referent)

1.00 (referent)

0.062

0.620

0.275

0.329

 

5′ near gene

GA

0.92 (0.63, 1.33)

0.70 (0.44, 1.10)

1.24 (0.70, 2.20)

1.21 (0.64, 2.28)

0.648

0.448

  
 

TFBS

AA

2.02 (1.04, 3.95)

2.10 (0.90, 4.98)

1.50 (0.54, 4.26)

1.04 (0.34, 3.20)

0.038

0.436

  
  

GA + AA

1.03 (0.72, 1.50)

0.81 (0.52, 1.30)

1.28 (0.74, 2.21)

1.15 (0.64, 2.10)

0.863

0.328

  
  

AA vs (GG + GA)

2.11 (1.10, 4.02)

2.49 (1.08, 5.72)

1.37 (0.50, 3.74)

1.02 (0.40, 2.98)

0.023

0.539

  

TNF

rs673

GG

1.00 (referent)

1.00 (referent)

1.00 (referent)

1.00 (referent)

0.027

0.452

0.279

0.874

 

5′ near gene

GA

1.50 (1.02, 2.20)

1.46 (0.92, 2.30)

1.22 (0.70, 2.14)

1.41 (0.76, 2.62)

0.025

0.498

  
 

TFBS

AA

0.24 (0.03, 1.84)

0.54 (0.06, 4.44)

0.33 (0.03, 3.24)

0.40 (0.03, 4.70)

0.116

0.315

  
  

GA + AA

1.38 (0.95, 2.00)

1.40 (0.88, 2.20)

1.14 (0.66, 2.00)

1.33 (0.72, 2.46)

0.087

0.635

  
  

AA vs (GG + GA)

0.21 (0.02, 1.60)

0.47 (0.06, 3.91)

0.31 (0.03, 2.98)

0.35 (0.03, 4.08)

0.080

0.286

  
  1. On a separate line before the text regarding the chi-square test p-values state the following:
  2. †Boldface odd ratios (ORs) and 95% confidence interval (CI) indicate a significant relationship between the selected SNPs and prostate cancer risk.
  3. ǂFrom top to bottom within the column, the chi-square test p-values were used to determine the difference in the genotype frequencies between cases and controls for the overall, minor/major versus major/major genotypes, as well as the dominant (i.e., minor/minor versus major/major), co-dominant (minor/minor + major/minor versus major/major), and recessive genetic models (minor/minor versus major/major + major/minor). P-values generated from the Fisher’s Exact test (in italics) were calculated when expected genotype counts were < 5 for either cases or controls. Statistically significant p-values are marked in bold face.
  4. Abbreviations: UTR, untranslated region; TFBS, transcription factor binding site; cds-syn, synonymous SNP; miRNA, microRNA binding site.
Back to article page

Hereditary Cancer in Clinical Practice

ISSN: 1897-4287